

Stem Cell and Regenerative Therapy: Global Markets

Market Research Report | 2026-02-09 | 168 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

Report description:

Description

Report Scope

The report provides an overview of the global stem cell and regenerative therapy market and analyzes market trends. The report includes global revenue (in \$ millions) for the base year data (2024) and estimated data for the forecast period (2025 through 2030). The market is segmented by product and services, application and region. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World, with a focus on major countries in each region.

The report focuses on significant trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses emerging technologies and the patent landscape related to the market.

The report concludes with an analysis of the competitive landscape, which provides the ranking or share of key companies in the global stem cell and regenerative medicine market, as well as a patent analysis. It also features a section with company profiles that provides overviews, key financials, product portfolios and recent developments of key market companies.

Report Includes

- 50 data tables and 62 additional tables
- Overview and an analysis of the global market for stem cell and regenerative therapy (medicines)
- Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects of the global market, along with a corresponding market share analysis based on product and service type, application and region
- Facts and figures pertaining to global market dynamics, advancements in therapy, regulations, prospects and the impact of macroeconomic factors
- Insights derived from Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Patent review, featuring key granted and published patents

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

- Review of emerging trends and technologies as well as new developments in the stem cell and regenerative therapy market
- Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives and venture fundings, and an investment outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Profiles of the leading companies, including Gilead Sciences Inc., Novartis AG, Bristol-Myers Squibb Co., Organogenesis Inc., and MiMedx Group Inc.

Executive Summary

Summary:

The global market for stem cell and regenerative therapy is projected to grow from an estimated \$16.7 billion in 2025 to \$43.8 billion by 2030, at a compound annual growth rate (CAGR) of 21.3% from 2025 to 2030.

Regenerative therapy employs cells, tissues or genetic material to replace, repair or regenerate damaged tissues or organs. Many chronic, fatal and difficult-to-treat illnesses such as cancer, Parkinson's disease, Alzheimer's disease, diabetes, kidney and cardiovascular diseases can be treated and potentially cured with regenerative therapy. Stem cell therapy is one of the most promising forms of medical treatment. Stem cells are being widely adopted across numerous applications, including neurological disorders, orthopedic treatments, oncology, diabetes, injuries and wounds, cardiovascular issues and more. Private organizations and governments in many countries recognize the benefits of stem cell therapies, leading to significant investments in stem cell research.

Private companies are investing in technological advances and optimizing cell culture technology to boost the production of low-cost therapeutics to meet growing demand for the treatment and prevention of chronic diseases. Technological advances focus on improving the stem cell culture process, which helps limit the overall cost of treatment and makes research easier for those using stem cell culture technology in their life science research. Advances have been made in stem cell culture media formulations, culture systems and equipment used in the development and processing of stem cells.

Table of Contents:

- Table of Contents
- Chapter 1 Executive Summary
 - Market Outlook
 - Scope of Report
 - Market Summary
 - Market Growth Factors
 - Emerging Technologies
 - Segmental Analysis
 - Regional Analysis
 - Conclusion
- Chapter 2 Market Overview
 - Technology Background
 - Stem Cell
 - Embryonic Stem Cells
 - Adult Stem Cells
 - Mesenchymal Stem Cells
 - Hematopoietic Stem Cells

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Neural Stem Cell
Endothelial Progenitor Cell
Epithelial Stem Cell
Very Small Embryonic-Like Cell
Cord Blood Stem Cell
Induced Pluripotent Stem Cells
Cell Therapy
A Brief History of CAR-T Cell Therapy
FDA Product Approvals
Gene Therapy
Evolution of Gene Therapy
Macroeconomic Factors Analysis
PESTEL Analysis
Impact of U.S. Tariff Laws on the Stem Cell and Regenerative Therapy Market
Porter's Five Forces Analysis
Potential for New Entrants (Moderate to High)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (High)
Threat of Substitutes (Low to Moderate)
Competition in the Industry (High)
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Growing Demand for Regenerative Medicines
Increasing Research and Regulatory Approval for Tissue Engineering Products
Rising Venture Capital Funding
Demand for an Effective Drug Discovery and Development Process
Rising Focus on Minimizing Animal Testing
Market Restraints
High Cost and Lack of Skilled Workforce
Complex Regulatory Framework
Market Opportunities
Technological Advances
Growth in iPSC Banking
Chapter 4 Regulatory Landscape
Overview
Gene Therapy Regulations
Cell Therapy Regulations
Viral and Non-Viral Vectors
Media
Regulatory Frameworks in the U.S.
Regulatory Frameworks in Europe
Cell and Gene Therapy Regulations in Europe
Regulatory Frameworks in Asia-Pacific
Chapter 5 Emerging Technologies and New Developments
Overview
Reprogramming Technologies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Gene Editing Technologies
3D Organoids
Artificial Intelligence in Stem Cell Research
Chapter 6 Market Segment Analysis
Segmentation Breakdown
Market Breakdown by Products and Services
Key Takeaways
Therapeutics
Tools and Reagents
Cell Banking
Market Breakdown by Application
Key Takeaways
Oncology
Orthopedic
Diabetes
Dermatology
Cardiovascular Disorders
Central Nervous System Disorders
Others
Geographic Breakdown
Market Breakdown by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Key Takeaways
Leading Players in the CGT Market, 2024
Leading Players in the Tissue Engineering Market, 2024
Strategic Analysis
Chapter 8 Sustainability in the Stem Cell and Regenerative Therapy Market: ESG Perspective
Sustainability: The Stem Cell and Regenerative Therapy Market
Understanding the ESG Data
Key ESG Issues
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC
Chapter 9 Patent Landscape
Key Takeaways
Patent Review
Gene Therapy Patents, by Year
Gene Therapy Patents, by Leading Applicants
Gene Therapy Patents, by Document Type
Cell Therapy Patents, by Year
Cell Therapy Patents, by Leading Applicants

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cell Therapy Patents, by Status
Tissue Engineering Patents, by Year
Tissue Engineering Patents, by Leading Applicants
Tissue Engineering Patents, by Status
Chapter 10 Appendix
Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
AMGEN INC.
BIOGEN
BLUEBIRD BIO INC. (GENETIX BIOTHERAPEUTICS INC.)
BRISTOL-MYERS SQUIBB CO.
CELLECTIS S.A.
CRISPR THERAPEUTICS
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
MIMEDX GROUP INC.
NOVARTIS AG
ORGANOGENESIS INC.
STRYKER
TECNOSS
ZIMMER BIOMET

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Stem Cell and Regenerative Therapy: Global Markets

Market Research Report | 2026-02-09 | 168 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-08"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com